Abstract: A method is provided for reversibly modifying a protein or peptide on its glutamine residue(s) by performing a reaction, such as a transglutaminase-catalyzed reaction, between the protein or peptide and an amine-containing reagent, whereby the reagent is linked through its amine function to a side chain of the glutamine residue. Subjecting the modified protein to an appropriate stimulus regenerates the protein or peptide in its original form.

Abstract: A method is provided for reversibly modifying a protein or peptide on its glutamine residue(s) by performing a reaction, such as a transglutaminase-catalyzed reaction, between the protein or peptide and an amine-containing reagent, whereby the reagent is linked through its amine function to a side chain of the glutamine residue. Subjecting the modified protein to an appropriate stimulus regenerates the protein or peptide in its original form.

Abstract: Compounds which are glycosylates of an A-ring of a cardiotonic steroid, wherein the steroid is attached to the anomeric position of (a) a monosaccharide comprising a C-4 amino group, or (b) an oligosaccharide are provided.

Abstract: A composition comprising an SL0101 [kaempferol 3-O-(3?,4?-di-O-acetyl-?-L-rhamnopyranoside)] derivative compound that has enhanced ability to inhibit RSK activity, relative to the parent compound is provided. The compounds have utility for treating any disease or conditions characterized or associated with excess or undesirable RSK activity. For example the RSK inhibitors of the present invention can be used to reduce the proliferation of neoplastic cells or for inhibiting the establishment or maintenance of an intracellular pathogenic infection by pathogens whose pathogenicity derives in part from the pathogen's ability to impede endosomal/phagosomal maturation in the host cell.

Abstract: A composition comprising an SL0101 [kaempferol 3-O-(3?,4?-di-O-acetyl-?-L-rhamnopyranoside)] derivative compound that has enhanced ability to inhibit RSK activity, relative to the parent compound is provided. The compounds have utility for treating any disease or conditions characterized or associated with excess or undesirable RSK activity. For example the RSK inhibitors of the present invention can be used to reduce the proliferation of neoplastic cells or for inhibiting the establishment or maintenance of an intracellular pathogenic infection by pathogens whose pathogenicity derives in part from the pathogen's ability to impede endosomal/phagosomal maturation in the host cell.

Abstract: A catheter device, comprising a venipuncture needle or stylet whose shank extends through the bore of a catheter or cannula and has a sharpened tip projecting slightly therebeyond in an extended position of the needle to provide an outside-the-needle catheter unit for venipuncture and for insertion of the catheter in a vein in largely conventional manner, and a housing adapted to define an elongate liquid flow chamber. Such housing is connected, liquid-tight, at one end to the catheter and is adapted to protectively house the sharpened tip of the needle following venipuncture. The housing itself is liquid-tight, except for an opening at its other end through which extends tubing for the supply of a venoclysis liquid. The other end of the needle may be provided with a hub formed as a stopper for fitting tightly in a seat formed in the housing immediately in advance of the opening, or may be provided with a hub that is attached to the supply tubing at the opening.